- Investopedia•8 hours ago
Celgene’s multiple sclerosis drug ozanimod beat rival Avonex in a Phase 3 study.
- Motley Fool•10 hours ago
Healthcare bargains abound for patient long-term investors.
- Reuters•11 hours ago
"We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that's for sure," chief executive officer Luigi Costa told Reuters. Nanovector is currently preparing a final test phase for its Betalutin drug candidate, a treatment for Non-Hodgkin Lymphoma (NHL) designed to attach itself to tumours in a novel way before killing them with a dose of radiation.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||288.60 x 100|
|Ask||289.00 x 900|
|Day's Range||287.76 - 291.90|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.07|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|